197 related articles for article (PubMed ID: 21365278)
21. Induction of adherent activity in mastocytoma P-815 cells by the cooperation of two prostaglandin E2 receptor subtypes, EP3 and EP4.
Hatae N; Kita A; Tanaka S; Sugimoto Y; Ichikawa A
J Biol Chem; 2003 May; 278(20):17977-81. PubMed ID: 12637575
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory effect of prostaglandin E(2) on the migration of nasal fibroblasts.
Shin JM; Park IH; Moon YM; Hong SM; Cho JS; Um JY; Lee HM
Am J Rhinol Allergy; 2014; 28(3):e120-4. PubMed ID: 24980222
[TBL] [Abstract][Full Text] [Related]
23. Prostanoid Receptors of the EP
Joshi R; Hamed O; Yan D; Michi AN; Mostafa MM; Wiehler S; Newton R; Giembycz MA
J Pharmacol Exp Ther; 2021 Feb; 376(2):161-180. PubMed ID: 33158942
[TBL] [Abstract][Full Text] [Related]
24. Activation of prostaglandin E2-EP4 signaling reduces chemokine production in adipose tissue.
Tang EH; Cai Y; Wong CK; Rocha VZ; Sukhova GK; Shimizu K; Xuan G; Vanhoutte PM; Libby P; Xu A
J Lipid Res; 2015 Feb; 56(2):358-68. PubMed ID: 25510249
[TBL] [Abstract][Full Text] [Related]
25. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation.
Kuriyama S; Kashiwagi H; Yuhki K; Kojima F; Yamada T; Fujino T; Hara A; Takayama K; Maruyama T; Yoshida A; Narumiya S; Ushikubi F
Thromb Haemost; 2010 Oct; 104(4):796-803. PubMed ID: 20664890
[TBL] [Abstract][Full Text] [Related]
26. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
Glenn JR; White AE; Iyu D; Heptinstall S
Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
[TBL] [Abstract][Full Text] [Related]
27. The EP1/EP3 receptor agonist 17-pt-PGE
Theiler A; Konya V; Pasterk L; Maric J; Bärnthaler T; Lanz I; Platzer W; Schuligoi R; Heinemann A
Vascul Pharmacol; 2016 Dec; 87():180-189. PubMed ID: 27664754
[TBL] [Abstract][Full Text] [Related]
28. Prostaglandin E₂ down-regulates the expression of CD25 on bovine T cells, and this effect is mediated through the EP4 receptor.
Maślanka T; Spodniewska A; Barski D; Jasiecka A; Zuśka-Prot M; Ziółkowski H; Markiewicz W; Jaroszewski JJ
Vet Immunol Immunopathol; 2014 Aug; 160(3-4):192-200. PubMed ID: 25001909
[TBL] [Abstract][Full Text] [Related]
29. Prostaglandin E2-stimulated prostanoid EP4 receptors induce prolonged de novo prostaglandin E2 synthesis through biphasic phosphorylation of extracellular signal-regulated kinases mediated by activation of protein kinase A in HCA-7 human colon cancer cells.
Fujino H; Seira N; Kurata N; Araki Y; Nakamura H; Regan JW; Murayama T
Eur J Pharmacol; 2015 Dec; 768():149-59. PubMed ID: 26518053
[TBL] [Abstract][Full Text] [Related]
30. Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMP‑PKA/PI3K‑Akt signaling pathway.
Xu S; Zhou W; Ge J; Zhang Z
Mol Med Rep; 2018 Mar; 17(3):4702-4712. PubMed ID: 29328471
[TBL] [Abstract][Full Text] [Related]
31. Prostaglandin E2 inhibits advanced glycation end product-induced adhesion molecule expression, cytokine production, and lymphocyte proliferation in human peripheral blood mononuclear cells.
Takahashi HK; Liu K; Wake H; Mori S; Zhang J; Liu R; Yoshino T; Nishibori M
J Pharmacol Exp Ther; 2009 Nov; 331(2):656-70. PubMed ID: 19700629
[TBL] [Abstract][Full Text] [Related]
32. Prostaglandin E(2) inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells.
Takahashi HK; Iwagaki H; Yoshino T; Mori S; Morichika T; Itoh H; Yokoyama M; Kubo S; Kondo E; Akagi T; Tanaka N; Nishibori M
J Immunol; 2002 May; 168(9):4446-54. PubMed ID: 11970988
[TBL] [Abstract][Full Text] [Related]
33. Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329.
Nitta M; Hirata I; Toshina K; Murano M; Maemura K; Hamamoto N; Sasaki S; Yamauchi H; Katsu K
Scand J Immunol; 2002 Jul; 56(1):66-75. PubMed ID: 12100473
[TBL] [Abstract][Full Text] [Related]
34. Opposing effects of prostaglandin E
Carboneau BA; Allan JA; Townsend SE; Kimple ME; Breyer RM; Gannon M
Mol Metab; 2017 Jun; 6(6):548-559. PubMed ID: 28580285
[TBL] [Abstract][Full Text] [Related]
35. Prostaglandin E(2) regulates murine hematopoietic stem/progenitor cells directly via EP4 receptor and indirectly through mesenchymal progenitor cells.
Ikushima YM; Arai F; Hosokawa K; Toyama H; Takubo K; Furuyashiki T; Narumiya S; Suda T
Blood; 2013 Mar; 121(11):1995-2007. PubMed ID: 23315170
[TBL] [Abstract][Full Text] [Related]
36. EP
Bradbury P; Rumzhum NN; Ammit AJ
J Cell Physiol; 2019 Jul; 234(7):11070-11077. PubMed ID: 30536718
[TBL] [Abstract][Full Text] [Related]
37. Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo.
Rao R; Redha R; Macias-Perez I; Su Y; Hao C; Zent R; Breyer MD; Pozzi A
J Biol Chem; 2007 Jun; 282(23):16959-68. PubMed ID: 17401137
[TBL] [Abstract][Full Text] [Related]
38. Cooperativity of E-prostanoid receptor subtypes in regulating signaling and growth inhibition in human airway smooth muscle.
Michael JV; Gavrila A; Nayak AP; Pera T; Liberato JR; Polischak SR; Shah SD; Deshpande DA; Penn RB
FASEB J; 2019 Apr; 33(4):4780-4789. PubMed ID: 30601680
[TBL] [Abstract][Full Text] [Related]
39. Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome.
Kim JI; Lakshmikanthan V; Frilot N; Daaka Y
Mol Cancer Res; 2010 Apr; 8(4):569-77. PubMed ID: 20353998
[TBL] [Abstract][Full Text] [Related]
40. PGE1 and PGE2 modify platelet function through different prostanoid receptors.
Iyú D; Jüttner M; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):9-16. PubMed ID: 21095237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
